- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01490853
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Remission With Interferon Based Therapy
Objectives
This is an observational study aimed at updating the overall survival (OS), the progression free survival (PFS) to accelerated-blastic (AB) phase and the complete cytogenetic response (CCgR) duration of the CML patients who between 1986 and 2001 were treated with an IFN based therapy (either alone or in combination) and who obtained a CCgR. It also aims at analysing the clinical and biological features of this selected cohort of patients with persisting CCgR after treatment with IFN.
Study design This study is an observational retrospective multicenter study.
Assessment and Follow-up Patients' demographic data and retrospective collection of CML cytogenetic and molecular data will be reported in the "Assessment and Follow-up FORM".
In this FORM the events related to therapy, disease and survival will also be reported.
Duration of the study:
The recruitment period is estimated in approximately 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study rational
- IFN, either alone or in combination with AC, prolonged survival of Ph+ CML patients, in early chronic phase, mainly in those patients achieving the CCgR
- CCgR became the surrogate marker for survival duration and the main target of IFN therapy
- CCgR were rare events accounting for less than 10% of the cytogenetic responsive patients
- These cases can be considered as a fascinating elite of patients who have the highest sensitivity to IFN and are the most likely candidates for prolonged survival and possibly cure
- From 1986 to 2001, more than 1200 CML patients either enrolled in different national trials or referred in single Institutions have been treated frontline with IFN based therapy
- In 2001, data on 317 CCgRs were reported by the EICML group
- They included 214 cases treated with IFN alone collected from the database of 9 national study groups in Austria, Belgium, Netherlands, France, Germany, Italy, Spain, Sweden and United Kingdom and 103 cases treated with IFN alone collected from single Institutions in Italy, France, and United Kingdom.
- The study did not include the patients achieving CCgR with IFN + LDAC
- The contribution of Italy was of 119 cases: 59 from national studies and 60 from single Institutions
- The follow-up of these patients is stopped at 2000 and from 2000 thereafter almost CML patients were treated with IM
- We don't know if the patients who had achieved a CCgR with IFN based therapy continued or discontinued IFN, or crossed to IM therapy
- We don't know if they maintained a CCgR with or without therapy
- We don't know if the patients who achieved a CCgR with IFN and crossed to IM had the same cytogenetic and molecular response, PFS and OS as the majority of the patients unresponsive to IFN who were treated with IM
- We don't know the clinical and biological features of these selected cohort of patients
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brescia, Italy, 25123
- Chair of Hematology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria
- Age > 18 years
- Ph+/BCR-ABL+ CML in CP
- Treatment with IFN alpha alone or in combination ( i.e HU, Ara-C, YNK01, ASCT ), either within or outside national Study Protocols.
- Complete cytogenetic response (CCgR) (0% Ph+ cells)
- Written informed consent prior to any study procedures being performed.
Exclusion Criteria:
- Patients with Ph+ CML in accelerated/blastic phase (AP/BP)
- No treatment with Interferon-alpha
- No written informed consent prior to any study procedures being performed.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CML and interpheron alpha
Adult Ph+CML pts in CCgR after IFN alpha.
|
Long term outcom after interferon alpha discontinuation or not
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: From date of enrollment until the date of first documented progression, assessed up to 240 months
|
One primary outcome measure is the PFS of the CML patients who between 1986 and 2001 were treated with IFN based therapy (either alone or in combination) and who obtained the CCgR.
|
From date of enrollment until the date of first documented progression, assessed up to 240 months
|
Duration of Complete Cytogenetic Response (CCgR)
Time Frame: From date of enrollment until the date of first documented loss of CCgR, assessed up to 240 months
|
One primary outcome measure is the duration of CCgR of the CML patients who between 1986 and 2001 were treated with IFN based therapy (either alone or in combination) and who obtained the CCgR.
|
From date of enrollment until the date of first documented loss of CCgR, assessed up to 240 months
|
Overall Survival
Time Frame: From date of enrollment until the date of first documented death from any cause, assessed up to 240 months
|
OS will be calculated from the date of diagnosis until date of death (whatever the cause).
Patients still alive will be censored at the moment of last follow-up.
|
From date of enrollment until the date of first documented death from any cause, assessed up to 240 months
|
Collaborators and Investigators
Investigators
- Study Director: Domenico Russo, Università degli Studi di Brescia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CML0509
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Emory UniversityTerminatedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
Clinical Trials on Interpheron alpha
-
Hospital Virgen de la SaludUnknown
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular DiseaseUnited States
-
University of California, Los AngelesCompleted
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingAutism Spectrum Disorder | Autistic Disorder | Fragile X Syndrome | Asperger SyndromeUnited States
-
Christina Murphey, RN, PhDTerminatedDepression | Insomnia | Anxiety | Sleep QualityUnited States
-
Christina Murphey, RN, PhDSuspended
-
Electromedical Products International, Inc.University of NottinghamRecruiting
-
Pennington Biomedical Research CenterQuest Nutrition LLCWithdrawnObesity | Cardiovascular DiseaseUnited States
-
Banc de Sang i TeixitsMinisterio de Sanidad, Servicios Sociales e Igualdad; Hospital Universitari...Completed
-
Brooke Army Medical CenterCompletedNeuropathic PainUnited States